Jenny Kim M.D., Ph.D., Associate Professor of Clinical Medicine
VAWMC Chief
Clinical Director of Aesthetic Surgery Westwood

Undergraduate Education
University of California, Berkeley

Medical Education
University of California,
Los Angeles, M.D., Ph.D.

Internship
Harbor-UCLA Medical Center,
Transitional/General Surgery

Residency Training
University of California, Los Angeles,
Dermatology
Harbor-UCLA Medical Center,
General Surgery

Fellowship Training
University of California, Los Angeles,
Mohs micrographic surgery, Lasers and Aesthetic Dermatology

Board Certification
Dermatology

Clinical Interest
Mohs micrographic skin cancer surgery, lasers and aesthetic dermatology


Biography

Jenny Kim, M.D., Ph.D. is an Associate Professor of Dermatology/Clinical Medicine at the David Geffen School of Medicine at UCLA and Chief of Dermatology at the Greater Los Angeles Healthcare System Veterans Affairs.  Dr. Kim received her M.D. and Ph.D. in Immunology from UCLA and also completed her Dermatology residency and Mohs Micrographic Surgery fellowship there.  She has been a UCLA faculty member since 2000 where she serves as referral source for patients requiring rejuvenation for aging skin and also for patients with skin cancers.  In her laboratory at the Center for Health Sciences, Dr. Kim studies the immune response in skin and is funded by the National Institutes of Health.

Dr. Jenny Kim provides total skin care consultation and planning.  Her philosophy is that skin must be nurtured and protected and she provides comprehensive analysis and services for healthy skin and rejuvenation. 

Currently Dr. Kim serves on various committees for the American Academy of Dermatology, Society for Investigative Dermatology, American Society for Dermatologic Surgery, American College of Mohs Micrographic Surgery and Women’s Dermatologic Society.  Dr. Kim is an editor for the Journal of Lasers and Cosmetic Surgery and a reviewer for the Journal of Investigative Dermatology.  Dr. Kim is a frequent consultant to pharmaceutical and cosmeceutical companies and serves as a member of Scientific Advisory Board for a number of pharmaceutical companies. 

Dr. Kim has been featured in the news and beauty magazines including the New York Times, Wall Street Journal, Los Angeles Times, Elle, Glamour, Men’s Journal and People magazine and in various radio and television shows for her expertise.

In addition to her academic endeavors, Dr. Kim is passionate about her philanthropic work.  She co-founded Camp Wonder in 2001, a camp that serves children with severe skin disorders which has served over 750 children since it’s inception.

 

Research Interest

Dr. Kim conducts both basic and clinical research in dermatologic science. In particular, her interest is in translational medicine, bringing scientific results from the bench to the bedside. Dr. Kim's laboratory currently focuses on three specific areas:
1.    Studying innate immunity in skin diseases.
2.    Investigating the mechanisms of inflammation, aging, and cancer.
3.    Developing novel therapy for skin infection, aging and cancer. Dr. Kim is involved with clinical trials that focus on anti-aging, aesthetic dermatology and new dermatology therapies that are immune-based. Current active clinical trial include the following: 1. Treatment of melomental fold rhytides with Nonanimal Sourced Hyaluronic Acid (NASHA) combined with Botulism toxin A (Botox) compared with NASHA alone.

Publications
Jalian HR, Liu PT, Kanchanapoomi M, Legaspi A, Modlin RL, Kim J. All-trans retinoic acid downregulates Propionibacterium acnes induced matrix metalloproteinase-1,9 and upregulates tissue inhibitors of metalloproteinase-1 in human monocytes. Journal of Investigative Dermatology 19 June 2008; doi:10.1038/jid.2008.    

Liu PT, Phan J, Tang D, Kanchanapoomi M, Hall B, Krutzik SR, Kim J. CD209+ macrophages mediate host defense against Propionibacterium acnes. Journal of Immunology 180:4919-23, 2008.    

McInturff J, Kim J. The Role of Toll: How therapies targeting Toll-like Receptors treat skin diseases. Drug Discovery Today:Therapeutic Strategies 3:75-80, 2006.    

Liu P, Krutzik S, Kim J, Modlin R. Cutting edge: All-trans retinoic acid downregulates Toll-like receptor-2 expression and function. Journal of Immunology, 174:2467-2470, 2005.    

McInturff J, Kim J. The Role of Toll: How therapies targeting Toll-like Receptors treat skin diseases. Drug Discovery Today:Therapeutic Strategies 3:75-80, 2006.